<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406392</url>
  </required_header>
  <id_info>
    <org_study_id>SUBMISO</org_study_id>
    <nct_id>NCT01406392</nct_id>
  </id_info>
  <brief_title>Sublingual Misoprostol for Induction of Labor</brief_title>
  <acronym>SUBMISO</acronym>
  <official_title>Sublingual Misoprostol 12,5 Mcg Versus Vaginal Misoprostol 25 Mcg for Induction of Labour of Alive and Term Fetus : Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Professor Fernando Figueira Integral Medicine Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maternidade Escola Assis Chateaubriand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Professor Fernando Figueira Integral Medicine Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare effectiveness and safety of a sublingual misoprostol
      12,5 mcg with vaginal misoprostol 25 mcg for induction of labour with an alive and term
      fetus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several methods for induction of labour are available. However, the most effective and with
      less frequency of adverse effects is still unknown. Vaginal misoprostol has been used
      frequently to induce labour but other routes of administrations have been proposed, such as
      oral and sublingual. The purpose of this study is to compare effectiveness and safety of
      sublingual misoprostol 12,5 mcg with vaginal misoprostol 25 mcg administration for induction
      of labour with an alive and term fetus. A randomized controlled double-blind trial will be
      carried in three hospitals: Instituto de Medicina Integral Prof. Fernando Figueira,
      Universidade Federal do Ceará and Instituto de Saúde Elpídio de Almeida and Maternidade da
      Universidade Federal de Campina Grande, from March 2011 to December 2011. A total of 150
      patients must be enrolled. Inclusion criteria are: a) indication for labour induction; b)
      term pregnancy with alive fetus; Bishop score less than six. Exclusion criteria are: a)
      previous uterine scar; b) nonvertex presentation; c) non-reassuring fetal status; d) fetal
      anomalies; e) fetal growth restriction; f) genital bleeding; g) tumors, malformations and/or
      ulcers of vulva, perineum or vagina. They will be randomized to receive a sublingual
      misoprostol 12,5 mcg with vaginal placebo tablet or sublingual placebo with vaginal
      misoprostol 25 mcg tablet. Vaginal tablets will have 25mcg of misoprostol or placebo.
      Sublingual tablet will have 12,5mcg or placebo. Vaginal misoprostol or placebo tablets will
      be administered for each six hours until the maximum dose of 200mcg or eight tablets. Primary
      outcome will be the frequency of tachysystole. Secondary outcomes will be vaginal delivery
      within 24 hours, hyperstimulation syndrome, cesarean section, severe neonatal morbidity or
      perinatal death, serious maternal morbidity or maternal death, need of oxytocin for
      augmentation of labour, number of misoprostol doses needed to bring on labour, interval from
      first dose to labour and first dose to delivery, failed induction, uterine rupture, need of
      labour analgesia, instrumental delivery, side effects, maternal death, meconium,
      non-reassuring fetal heart rate, Apgar scores less than seven at 1st and 5th minutes,
      admission at neonatal intensive care unit, neonatal encephalopaty, perinatal death and women
      not satisfied.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of taquissistoly</measure>
    <time_frame>48 hours</time_frame>
    <description>during 48 hours the presence of taquissistoly will be observed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hyperstimulation Syndrome</measure>
    <time_frame>48 hours</time_frame>
    <description>during 48 hours the presence of hyperstimulation syndrome will be observed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Labor</condition>
  <condition>Induced</condition>
  <arm_group>
    <arm_group_label>Sublingual Misoprostol 12,5mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sublingual misoprostol or placebo tablete will be administered for each six hours until the maximum dose of 100mcg or eight tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal Misoprostol 25 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets. Each pacient will receve at the same time a sublingual placebo tablet and vaginal misoprostol or sublingual misoprostol and vaginal placebo tablet. It will depend of the randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol 25mcg</intervention_name>
    <description>Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.</description>
    <arm_group_label>Vaginal Misoprostol 25 mcg</arm_group_label>
    <other_name>Prostokos Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual Misoprostol</intervention_name>
    <description>Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets</description>
    <arm_group_label>Sublingual Misoprostol 12,5mcg</arm_group_label>
    <other_name>Prostokos</other_name>
    <other_name>Cytotec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for labour induction

          -  Term pregnancy with alive fetus

          -  Bishop score less than six

        Exclusion Criteria:

          -  Previous uterine scar

          -  Nonvertex presentation

          -  Non-reassuring fetal status

          -  Fetal anomalies

          -  Fetal growth restriction

          -  Genital bleeding

          -  Tumors, malformations and/or ulcers of vulva, perineum or vagina
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniele SM Gattás, MD student</last_name>
    <phone>55 81 88986853</phone>
    <email>djgattas@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>: Alex SR Souza, PhD student</last_name>
    <phone>55-81-32217924</phone>
    <email>alexrolland@uol.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto de Medicina Integral Professor Fernando Figueira (IMIP)</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50070-550</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele SM Gattás, MD Student</last_name>
      <phone>55 81 88986853</phone>
      <email>djgattas@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2011</study_first_submitted>
  <study_first_submitted_qc>July 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <last_update_submitted>July 29, 2011</last_update_submitted>
  <last_update_submitted_qc>July 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Daniele Sofia de Moraes Barros Gattás</name_title>
    <organization>MD Student</organization>
  </responsible_party>
  <keyword>Misoprostol</keyword>
  <keyword>Sublingual</keyword>
  <keyword>Induced</keyword>
  <keyword>Labor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

